VaxartVaxart reports mixed PhII data for norovirus vaccine; J&J to proceed with Cidara influenza deal
2023-09-07
临床结果临床2期疫苗
Vaxart announced on Wednesday that a Phase II study of its oral norovirus vaccine achieved the primary endpoint of reducing the rate of infection. The vaccine is designed to go after the norovirus GI.1 genotype, which causes gastroenteritis.
However, in the trial’s other primary endpoint, the vaccine achieved a 21% reduction in norovirus acute gastroenteritis, which was not statistically significant against the placebo. VaxartVaxart is planning to analyze the Phase II data further. — Tyler Patchen
Preview
来源: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。